A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma

Exclusion Criteria

• •Known symptomatic brain metastases requiring \>10 mg/day of prednisolone.
• •Significant cardiovascular disease.
• •Known active HBV, HCV, AIDS-related illness.
• •Has received a live vaccine within 30 days.
• •History of active autoimmune disorders, or ongoing immunosuppressive therapy.
• •Continuance of toxicities due to prior radiotherapy or chemotherapy agents that do not recover to \< Grade 2.
• •Receiving concurrent anti-cancer therapy, investigational product, strong inhibitors or inducers of cytochrome P450 3A (CYP3A) .
• •Prior treatment with other hematopoietic progenitor kinase 1 (HPK1) inhibitors.
• •Allergy to the ingredients of study drug, or a history of other allergies which were judged by the investigator to be unsuitable for participation in the study.